Navigation Links
New drug candidate reduces blood lipids
Date:3/10/2010

A thyroid-hormone-like substance that works specifically on the liver reduces blood cholesterol with no serious side effects. This according to a clinical trial conducted by researchers from the Swedish medical university Karolinska Institutet, amongst other centres, published today in the top-ranking scientific periodical The New England Journal of Medicine.

High cholesterol levels in the blood are primarily treated with a group of drugs called statins, but they are not always sufficiently effective and higher doses commonly cause adverse reactions. A team of researchers, including scientists from Karolinska Institutet, have now shown in a clinical trial that a new drug substance called eprotirome can reduce blood cholesterol effectively in patients who have already received statins. Patients who were given supplementary medication with eprotirome demonstrated levels of harmful blood fats that were up to 30 per lower than those of patients who received a placebo supplementary treatment.

The trial lasted three months and included a total of 189 patients. It remains to be studied whether the drug candidate will be equally safe and effective for a larger group of patients over a longer period of time.

"This drug could help patients who react adversely to statins or be used as a supplementary treatment for those who don't respond well to them," says Professor Bo Angelin, who led the study.

Eprotirome mimics the natural ability of thyroid hormone to stimulate the metabolism of cholesterol, and exerts its effects exclusively on the liver. The development of similar non-selective drugs has previously been stopped on account of the serious adverse effects they have had on other organ systems (e.g. cardiac dilatation and osteoporosis) or on the physiological regulation of thyroid hormones.

Eprotirome has been developed by pharmaceutical company KaroBio in Huddinge, which is financing and participating in the research.


'/>"/>

Contact: Katarina Sternudd
katarina.sternudd@ki.se
46-852-483-895
Karolinska Institutet
Source:Eurekalert

Related medicine news :

1. Addiction Industry Thrives Amidst Economic Climate, Seeks Certified Candidates
2. Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study
3. VHGI: VHGI Gold Targets Candidates to Fill Key Advisory Board Position to Evaluate International Mining Acquisitions; Internet Town Hall Meeting Details Emerge, Kitco Gold Coverage Initiated
4. Candidate Potential Report Reduces Risk of Bad Hires
5. Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology
6. Pitt researchers find candidates for new HIV drugs
7. AlphaRx Presents Company Overview and New Product Candidates at the Rodman Renshaw Healthcare Conference
8. EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction
9. Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy
10. U.S. Senate Candidate Cheryle Jackson: Public Option Critical to Real Health Care Reform
11. DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... 22, 2017 , ... Silicon Valley startup Enke Life has ... Their electric toothbrushes aggressively attack oral bacteria by reducing dental plaque and other ... edge Enke technology with a premium timeless design, they want to redefine the ...
(Date:9/22/2017)... ... September 22, 2017 , ... Egg ... life. Although frozen embryos have a slight statistical advantage for live births, frozen ... a wonderful opportunity for women undergoing medical treatment or who are concerned about ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability Indices for ... 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality in device ... of The Quality System Regulation (§820.250), and Devicemakers find themselves staring at a ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... of a new member survey conducted by the International Society of Hair ... from 2014 to 2016 rose 60 percent, with 635,189 procedures performed in 2016. ...
(Date:9/21/2017)... ... 21, 2017 , ... Innovatum will demonstrate capabilities of fully ... Conference 2017 in Chicago, IL on October 17-19, 2017. This unique development addresses ... patient safety. , Microscan , a global technology leader in barcoding, ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly and ... will present new data for galcanezumab and lasmiditan, two ... the International Headache Society (IHC) taking place Sept. 7-10 ... Lilly will highlight new, long-term data from an open-label ... of galcanezumab (120 mg and 240 mg) for the ...
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
(Date:8/29/2017)... , Aug. 29, 2017 ivWatch, LLC, the leading provider ... infiltrations, announced it has been awarded an Innovative Technology contract from ... the country. ... device to aid in the early detection of peripheral IV infiltration ... The Innovative Technology contract ...
Breaking Medicine Technology: